Ayurvedic manangement of Adolescent Nonalcoholic fatty liver disease
Phase 3
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
- Registration Number
- CTRI/2023/04/051376
- Lead Sponsor
- All India Institute of Ayurveda, New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient with liver stiffness 7.1 to 9.9 kPa in FibroScan.
Exclusion Criteria
Patients with
1.documented cause of chronic liver disease other than NASH
2.suffering from anemia and other diseases that could increase ALT levels such as Hepatitis, Positive HBsAg, positive anti-human immunodeficiency virus, positive hepatitis C virus-RNA.
3.History of drugs known to induce steatosis (systemic glucocorticoids, tetracycline, anabolic steroids, salicylates, tamoxifen, valproate, amiodarone, or prednisone).
4.History of drugs known to induce affect body weight (Treatment with phentermine, lorcaserin orlistat, zonisamide, topiramate, bupropion, or naltrexone).
5.Autoimmune liver disease, metabolic liver disease, Wilson disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in score of Liver stiffness in FibroScanTimepoint: Before treatment 0 day and after treatment 90th day.
- Secondary Outcome Measures
Name Time Method Reduction of Paediatric NAFLD fibrosis score.Timepoint: 0 day - 90th day